What are the indications, recommended dosing, and contraindications for Etoricoxib in adult patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Etoricoxib: Indications, Dosing, and Contraindications

Etoricoxib is a highly selective COX-2 inhibitor approved for osteoarthritis (60 mg daily), rheumatoid arthritis (90 mg daily), ankylosing spondylitis (90 mg daily), and acute gouty arthritis (120 mg daily), but it carries significant cardiovascular risks and is contraindicated in patients with ischemic heart disease, stroke, or uncontrolled hypertension. 1, 2, 3

Approved Indications and Dosing

Etoricoxib demonstrates the highest COX-1/COX-2 selectivity ratio among available COX-2 inhibitors, exceeding rofecoxib, valdecoxib, and celecoxib 1. The drug is administered once daily due to its approximately 20-hour elimination half-life 4.

Specific dosing by indication:

  • Osteoarthritis: 60 mg once daily 1, 5
  • Rheumatoid arthritis: 90 mg once daily 1, 3
  • Ankylosing spondylitis: 90 mg once daily 2, 3
  • Acute gouty arthritis: 120 mg once daily 1, 6

The 120 mg dose for acute gout provides equivalent efficacy to indomethacin and diclofenac but with superior gastrointestinal tolerability 6. For postoperative pain, single doses of 120 mg produce high-quality analgesia with a number needed to treat (NNT) of 1.8, comparable to or better than other commonly used analgesics 7.

Efficacy Profile

Etoricoxib demonstrates clinical efficacy equivalent to traditional NSAIDs across all approved indications 3, 5. In dose-ranging studies for osteoarthritis, maximal efficacy was achieved at 60 mg daily, with sustained effects over 14 weeks 5. The drug provides similar symptomatic relief to nonselective NSAIDs and celecoxib while significantly reducing gastrointestinal adverse events by approximately 50% compared to diclofenac 2, 3.

Cardiovascular Risk Profile

Critical cardiovascular considerations:

The MEDAL program, which randomized 34,701 patients with osteoarthritis or rheumatoid arthritis to etoricoxib versus diclofenac, demonstrated non-inferiority for thrombotic cardiovascular events (hazard ratio 1.02,95% CI 0.87-1.18) 8. However, this finding requires careful interpretation—both etoricoxib and diclofenac lie on the highly COX-2-selective end of the spectrum, and diclofenac itself carries increased cardiovascular risk 8. Meta-analyses show COX-2 inhibitors as a class increase myocardial infarction risk with a rate ratio of 1.86 (1.33 to 2.59) compared to placebo 8.

Etoricoxib is absolutely contraindicated in:

  • Ischemic heart disease
  • Cerebrovascular disease (prior stroke)
  • Uncontrolled hypertension 2, 3

Rates of discontinuation due to hypertension-related adverse effects are higher with etoricoxib than diclofenac 2. Like all NSAIDs, etoricoxib raises blood pressure and increases thrombotic cardiovascular event risk through COX-2-mediated suppression of prostacyclin production while leaving platelet thromboxane A2 production intact 8.

Gastrointestinal Safety

Etoricoxib provides superior gastrointestinal safety compared to traditional NSAIDs. The drug significantly reduces uncomplicated upper GI adverse events and discontinuation rates due to GI complications by 50% versus diclofenac 2, 3. This advantage stems from selective COX-2 inhibition, sparing COX-1-mediated gastroprotective prostaglandin synthesis 8.

However, risk factors that increase NSAID-related GI complications still apply:

  • Prior peptic ulcer disease (2-4 fold increased risk—the most significant factor)
  • Prior NSAID GI complication
  • Advanced age (4% increased risk per year)
  • Concomitant corticosteroids or anticoagulants
  • Concurrent low-dose aspirin (>10-fold increased risk when combined with NSAIDs) 9

Additional Contraindications and Precautions

Beyond cardiovascular contraindications, etoricoxib shares class-wide NSAID warnings:

Absolute contraindications:

  • Active peptic ulcer disease or GI bleeding
  • Severe hepatic impairment (AUC increases 40% in moderate hepatic impairment) 4
  • Severe renal failure
  • Inflammatory bowel disease
  • Pregnancy (third trimester)

Use with extreme caution or avoid:

  • Concurrent aspirin therapy (negates GI benefit and increases cardiovascular risk)
  • Multiple NSAID use
  • Anticoagulant or antiplatelet therapy
  • History of hypersensitivity to NSAIDs or aspirin 9

Rare but Serious Adverse Events

Recent case reports document severe hypersensitivity reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, fixed drug eruptions, acute generalized exanthematous pustulosis, and drug-induced thrombocytopenia and immune hemolytic anemia 10. While infrequent, these reactions carry significant morbidity and mortality risk. Immediate drug discontinuation is mandatory upon clinical suspicion of severe cutaneous or hematological reactions.

Clinical Decision Algorithm

For patients requiring NSAID therapy, select etoricoxib when:

  1. High GI risk (prior ulcer, age >65, concurrent corticosteroids) AND
  2. Low cardiovascular risk (no ischemic heart disease, stroke, or uncontrolled hypertension) AND
  3. Chronic inflammatory arthropathy requiring sustained COX-2 inhibition 2, 3, 11

Do NOT use etoricoxib if:

  • Any cardiovascular disease or uncontrolled hypertension present
  • Patient requires concurrent aspirin (use traditional NSAID + PPI instead)
  • Acute pain management in cardiovascular disease patients (consider alternative analgesics)

The drug should be prescribed at the lowest effective dose for the shortest duration necessary, recognizing that cardiovascular risk appears cumulative and linear with NSAID exposure 9, 8.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.